Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

TRANSPLANTATION is a premier journal in the field of organ transplantation, published by Lippincott Williams & Wilkins, that has been a cornerstone of transplantation research since its inception in 1963. With an impressive impact factor cementing its status, this journal is categorized in the top quartile (Q1) of its field, currently ranking 6th out of 54 in the Scopus Medicine Transplantation category, placing it in the 89th percentile. The journal publishes original research, clinical studies, and reviews that significantly advance our understanding of transplantation science, ensuring that professionals, researchers, and students remain informed of the latest developments. Although it is not an open-access journal, it offers valuable insights that contribute to enhancing practice and improving outcomes in transplantation medicine, making it an essential resource for anyone involved in this dynamic and impactful discipline.

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

TRANSPLANT INTERNATIONAL is a premier open-access journal in the field of transplantation, published by Frontiers Media SA since 1988. With its dedicated scope encompassing the latest research and advancements in organ transplantation and related fields, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals engaged in transplantation medicine. Boasting an impressive 2023 Scopus rank of #17 out of 54 in the Medicine - Transplantation category and a Q2 quartile ranking, it has established itself as a vital publication platform contributing to the global discourse on transplant innovations. As an open-access journal since 2022, TRANSPLANT INTERNATIONAL enhances the dissemination of knowledge, ensuring that pivotal findings are accessible to a broader audience, thereby fostering advancements in patient care and clinical practices. With its base in Italy and operations managed from Lausanne, Switzerland, the journal promises to remain at the forefront of transplantation research through 2024 and beyond.

Stem Cells International is a premier open access journal published by HINDAWI LTD, focusing on the rapidly evolving field of stem cell research. With an ISSN of 1687-966X and E-ISSN 1687-9678, this journal has been a vital resource since its inception in 2010, showcasing innovative studies and breakthroughs up to 2024. Positioned in Q3 in Cell Biology and Q2 in Molecular Biology for 2023, as well as well-ranked in the Scopus database, the journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the implications of stem cell technology in regenerative medicine and biological research. The open access model ensures wide accessibility, fostering collaboration and knowledge-sharing across the scientific community, making it a cornerstone in advancing the understanding and application of stem cell science.

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.

Tissue Engineering Part B-Reviews is a premier academic journal published by MARY ANN LIEBERT, INC, focusing on the interdisciplinary field of tissue engineering and regenerative medicine. With an impressive impact factor that places it in the Q1 category across multiple relevant fields—including Biochemistry, Bioengineering, Biomaterials, and Biomedical Engineering—this journal provides a vital platform for researchers and professionals to disseminate cutting-edge findings and comprehensive reviews. Covering a vast scope from 2008 to 2024, the journal is committed to advancing knowledge in the application of engineering principles to biological tissues, making it an indispensable resource for those at the forefront of biomedical innovation. While the journal does not currently offer open access options, its rigorous peer review process ensures high-quality contributions that are essential for academic and practical advancements. The journal's rankings in Scopus reflect its significance, catering to a diverse audience of students, researchers, and practitioners seeking the latest insights in this dynamic field.

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Transplantation and Cellular Therapy is a leading journal published by Elsevier Science Inc, dedicated to advancing the fields of transplantation, immunology, cell biology, and molecular medicine. With its ISSN of 2666-6375 and E-ISSN 2666-6367, this journal serves as a vital resource for researchers, practitioners, and students aiming to stay at the forefront of innovative therapies and clinical practices in transplantation. As of 2023, it holds an impressive Q1 ranking in multiple categories, including Cell Biology, Hematology, Immunology and Allergy, Molecular Medicine, and Transplantation, reflecting its high impact and relevance in the scientific community. The journal, operating from its base in the Netherlands, supports Open Access publishing to enhance the dissemination and accessibility of groundbreaking research. Acknowledging the significance of transplantation and cellular therapies in modern medicine, Transplantation and Cellular Therapy is poised to propel future discoveries and developments in these critical domains.

Vestnik Transplantologii i Iskusstvennyh Organov, published by the Federal Research Center Transplantology & Artificial Organs V I Shumakov, is an esteemed open access journal that has been disseminating critical research in the fields of transplantation and immunology since 2009. With an ISSN of 1995-1191 and E-ISSN 2412-6160, this journal serves as a vital resource for academics and practitioners alike, offering insights into current trends, innovations, and methodologies in organ transplantation. The journal is indexed in prominent databases, holding a Q4 category in Immunology and Allergy and a Q3 in Transplantation as of 2023, ranking 42nd out of 54 in the field of Medicine - Transplantation, and 208th out of 233 in Medicine - Immunology and Allergy. Through its commitment to open access publishing and its strategic focus on advancing the science of transplantology, Vestnik Transplantologii i Iskusstvennyh Organov contributes significantly to the global body of knowledge, promoting collaboration and engagement among researchers, healthcare professionals, and students from around the world.